Cellectar Biosciences

CLRB

Market cap $21.9M

Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in  Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy

Cellectar Biosciences, Inc. (CLRB) Q1 2026 Earnings Call Transcript

Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM)

FLORHAM PARK, N.J., May 11, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the Company will report financial results for the first quarter ended March 31, 2026, and provide a corporate update on May 14, 2026, at 8:30 a.m. Eastern Time.

Cellectar Biosciences (CLRB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Cellectar Biosciences Inc (NASDAQ:CLRB) shares are down during Wednesday's premarket session after the stock closed almost 12% higher on Tuesday after positive clinical trial data and financing efforts.

Cellectar Biosciences, Inc. (NASDAQ:CLRB) shares are up during Tuesday's trading session as the company announced promising results from its Phase 2b CLOVER WaM clinical trial.

83.6% ORR and 61.8% MRR achieved in heavily pretreated population with median duration of response of 17.8 months FDA-requested dataset with ≥12-month follow-up on all patients strengthens regulatory positioning for accelerated approval and supports initiation of confirmatory trial in 4Q26 Compelling efficacy observed in post-BTKi patients, including ~64% MRR and durable responses exceeding 18 months Recently Announced Oversubscribed Financing of up to $140 Million with Leading Healthcare Institutional Investors Supports Confirmatory Study and NDA Filing for Accelerated Approval of Iopofosine I 131 in Waldenström Macroglobulinemia with the FDA FLORHAM PARK, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of targeted oncology therapies, today announced updated and mature 12-month follow-up data from its Phase 2b CLOVER WaM clinical trial evaluating iopofosine I 131 in patients with relapsed or refractory (r/r) Waldenström macroglobulinemia (WM).

Oversubscribed Financing Led by Nantahala Capital with Participation from Balyasny Asset Management, Caligan Partners, Janus Henderson Investors, SilverArc Capital Management, Stonepine Capital Management, Empery Asset Management LP, StemPoint Capital LP and other Dedicated Healthcare Funds along with Members of the Executive Management Team Financing of up to $140 Million Supports Confirmatory Study and NDA Filing for Accelerated Approval of Iopofosine I 131 in Waldenström Macroglobulinemia with the FDA Andrew Gu of Nantahala Capital Management, LLC to Join the Company's Board of Directors Upon Closing FLORHAM PARK, N.J., May 05, 2026 (GLOBE NEWSWIRE) --  Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of targeted oncology therapies, today announced that it has entered into a securities purchase agreement with certain institutional investors, and an additional securities purchase agreement with certain members of management, to issue and sell up to an aggregate of approximately $35 million upfront and $105 million in milestone-based securities in a registered direct offering of common stock and a concurrent private placement of common stock, pre-funded warrants, and milestone-based warrants.

Study will evaluate tumor-specific uptake, safety, tolerability, and preliminary efficacy signals of CLR 125 in refractory TNBC, to determine recommended Phase 2 dose Study will evaluate tumor-specific uptake, safety, tolerability, and preliminary efficacy signals of CLR 125 in refractory TNBC, to determine recommended Phase 2 dose